Smith+Nephew’s TESSA Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation
AI-summarised brief · reviewed before publication
Smith+Nephew announced that the U.S. Food and Drug Administration granted De Novo classification for its TESSA Spatial Surgery System. This regulatory approval marks the first device in a new FDA category for intra-articular orthopedic stereotaxic navigation instruments. The system utilizes AI, augmented reality, and real-time tracking to enhance arthroscopic procedures. It generates patient-specific 3D anatomical models from preoperative scans, overlaying them onto live 4K video to assist surgeons. The initial indication is for femoral tunnel placement during anterior cruciate ligament reconstruction, addressing common causes of surgical failure like malposition. Developed using technology from acquired Perceive3D S.A., the platform runs on AWS and NVIDIA infrastructure. Experts note this innovation supports clinical decision-making rather than replacing it. The classification establishes a regulatory reference point for future digital sports medicine tools, reinforcing Smith+Nephew’s position in personalized, data-enabled surgical solutions. This milestone signifies a generational leap in procedural precision and personalized planning for orthopedic surgeons treating knee injuries.
💡 Why It Matters
- · By establishing a new regulatory category, this approval creates a precedent for AI-driven surgical navigation tools, potentially accelerating the adoption of augmented reality in orthopedics.
- · It shifts the industry focus from implant-centric solutions to data-enabled procedural precision, setting a new standard for reducing surgical errors in complex reconstructions.